Week 1: Parkinson’s Disease

Course length

3 to 4 hours

Facilitators

Week 1: Parkinson’s Disease

Spyridon Konitsiotis

Week 1: Parkinson’s Disease

Dimitrios Fotiadis

Week 1: Parkinson’s Disease

Week 1: Parkinson’s Disease

About the course

Part 1: Facts, cause, diagnosis and symptoms
Part 2: Expected impact of diagnosis, prognosis and importance of timely integration of Palliative Care

Learning Objectives

Getting familiar with Parkinson’s Disease in terms of epidemiology and prevalence, known causes including genetics, environmental and their interactions, how diagnosis is made and communicated and which are the main symptoms.
Understanding the impact of PD to patients and their caregivers and how the early and timely integration of palliative care can help deal with it.

Summary & Scheduling

Part 1: Facts, cause, diagnosis and symptoms
Part 2: Expected impact of diagnosis, prognosis and importance of timely integration of Palliative Care

Learning Content

Attitude: The clinicians are encouraged to be respectful towards patients and caregivers need for information. To encourage patients and caregivers ask the questions. Knowledge: Participants know the basics of PD, specifically:
• What PD is
• The factors that modify the risk of developing PD
• The pathogenetic mechanisms that lead to the degeneration of PD
• The clinical features of the disorder
• The presentation and diagnosis of PD
• What is the prognosis of the disease and the timing of introducing Palliative Care
Skills: Clinicians are able to recognise PD and its complex symptoms and discuss disease management with their patients and caregivers.

Teaching Methods

• Presentation (slides)
• Video component
• Reading materials

Literature

• Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124(8):901–905.
• Miller IN, Cronin-Golomb A. Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov Disord. 2010;25(16):2695–2703.
• Billingsley KJ, Bandres-Ciga S, Saez-Atienzar S, Singleton AB. Genetic risk factors in Parkinson's disease. Cell Tissue Res. 2018;373(1):9–20.
• Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem. 2016;139 Suppl 1(Suppl 1):59–74.
• Ball N, Teo WP, Chandra S, Chapman J. Parkinson's Disease and the Environment. Front Neurol. 2019;10:218. Published 2019 Mar 19.
• Surmeier DJ. Determinants of dopaminergic neuron loss in Parkinson's disease. FEBS J. 2018;285(19):3657–3668.
• Cherubini M, Wade-Martins R. Convergent pathways in Parkinson's disease. Cell Tissue Res. 2018;373(1):79–90.
• Marsili L, Rizzo G, Colosimo C. Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. Front Neurol. 2018;9:156. Published 2018 Mar 23.
• Vu TC, Nutt JG, Holford NH. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. Br J Clin Pharmacol. 2012;74(2):267–283.
• Sarafis P, Tsounis A, Malliarou M, Lahana E. Disclosing the truth: a dilemma between instilling hope and respecting patient autonomy in everyday clinical practice. Glob J Health Sci. 2013;6(2):128–137. Published 2013 Dec 20.
• van der Steen JT, Lennaerts H, Hommel D, et al. Dementia and Parkinson's Disease: Similar and Divergent Challenges in Providing Palliative Care. Front Neurol. 2019;10:54. Published 2019 Mar 11

Assessment

• Presentation (slides)
• Video component
• Reading materials